Transgene Biotek (BOM:526139) Debt-to-Asset : 0.10 (As of Mar. 2025)

View and export this data going back to 2001. Start your Free Trial

What is Transgene Biotek Debt-to-Asset?

Transgene Biotek's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹84.17 Mil. Transgene Biotek's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹61.03 Mil. Transgene Biotek's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was ₹1,440.92 Mil. Transgene Biotek's debt to asset for the quarter that ended in Mar. 2025 was 0.10.

Transgene Biotek Debt-to-Asset Historical Data

The historical data trend for Transgene Biotek's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Biotek Debt-to-Asset Chart

Transgene Biotek Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-Asset

Get a 7-Day Free Trial

0.07

0.08

0.09

0.10

Transgene Biotek Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															0.10	-	0.10	-	0.10

Competitive Comparison of Transgene Biotek's Debt-to-Asset

For the Biotechnology subindustry, Transgene Biotek's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Biotek's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Transgene Biotek Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Transgene Biotek's Debt-to-Asset for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(84.17	+	61.029)	/	1440.916
	=	0.10

Transgene Biotek's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(84.17	+	61.029)	/	1440.916
	=	0.10

Transgene Biotek (BOM:526139) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Transgene Biotek Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Transgene Biotek's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Biotek Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene Biotek Ltd (BOM:526139) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325

Website

https://www.transgenebiotek.com

Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.

Transgene Biotek Headlines

No Headlines